Recombinant Complement Factor I (CFI) | MyBioSource MBS2010366 product information

product summary

company name :

MyBioSource

product type :

protein

product name :

Recombinant Complement Factor I (CFI)

catalog :

MBS2010366

quantity :

0.01 mg

price :

185 USD

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS2010366

products type :

Recombinant Protein

products full name :

Recombinant Complement Factor I (CFI)

products short name :

Complement Factor I (CFI)

other names :

complement factor I preproprotein; Complement factor I; complement factor I; C3b-inactivator; C3B/C4B inactivator; complement component I; light chain of factor I; Konglutinogen-activating factor; complement factor I heavy chain; complement control protein factor I; complement factor I; C3B/C4B inactivator

products gene name :

CFI

other gene names :

CFI; CFI; FI; IF; KAF; AHUS3; ARMD13; C3BINA; C3b-INA; IF

uniprot entry name :

CFAI_HUMAN

host :

E Coli

sequence length :

583

sequence :

The target protein is fused with N-terminal His-Tag, its sequence is listed below. MGHHHHHHSG SEF-I VGGKRAQLGD LPWQVAIKDA SGITCGGIYI GGCWILTAAH CLRASKTHRY QIWTTVVDWI HPDLKRIVIE YVDRIIFHEN YNAGTYQNDI ALIEMKKDGN KKDCELPRSI PACVPWSPYL FQPNDTCIVS GWGREKDNER VFSLQWGEVK LISNCSKFYG NRFYEKEMEC AGTYDGSIDA CKGDSGGPLV CMDANNVTYV WGVVSWGENC GKPEFPGVYT KVANYFDWIS YHVGRPFISQ YNV

purity :

> 95%

form :

Supplied as lyophilized form in 20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5% trehalose, and preservative.

storage stability :

Avoid repeated freeze/thaw cycles. Store at 2-8 degree C for one month. Aliquot and store at -80 degree C for 12 months. Stability Test: The thermal stability is described by the loss rate of the targetprotein. The loss rate was determined by accelerated thermal degradation test,that is, incubate the protein at 37 degree C for 48h, and no obvious degradation andprecipitation were observed. (Referring from China Biological Products Standard,which was calculated by the Arrhenius equation.) The loss of this protein is lessthan 5% within the expiration date under appropriate storage condition.

tested application :

SDS-PAGE, Western Blot (WB), ELISA (EIA), Immunoprecipitation (IP)

other info1 :

Organism: Homo sapiens (Human). Expression System: Prokaryotic expression. Residues: Ile340~Val583 (Accession # P05156) with N-terminal His-Tag. Subcellular Location: Secreted, extracellular space

other info2 :

Endotoxin Level: <1.0EU per 1ug (determined by the LAL method). Predicted Isoelectric Point: 6.4. Reconstitution: Reconstitute in ddH2O.

ncbi gi num :

119392081

ncbi acc num :

NP_000195.2

ncbi gb acc num :

NM_000204.3

uniprot acc num :

P05156

ncbi mol weight :

29.1kDa

ncbi pathways :

Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484); Complement Cascade Pathway (106405); Immune System Pathway (106386); Innate Immune System Pathway (106387); Regulation Of Complement Cascade Pathway (576254); Staphylococcus Aureus Infection Pathway (172846); Staphylococcus Aureus Infection Pathway (171867)

ncbi summary :

This gene encodes a serine proteinase that is essential for regulating the complement cascade. The encoded preproprotein is cleaved to produce both heavy and light chains, which are linked by disulfide bonds to form a heterodimeric glycoprotein. This heterodimer can cleave and inactivate the complement components C4b and C3b, and it prevents the assembly of the C3 and C5 convertase enzymes. Defects in this gene cause complement factor I deficiency, an autosomal recessive disease associated with a susceptibility to pyogenic infections. Mutations in this gene have been associated with a predisposition to atypical hemolytic uraemic syndrome, a disease characterized by acute renal failure, microangiopathic hemolytic anemia and thrombocytopenia. Primary glomerulonephritis with immmune deposits is another condition associated with mutation of this gene. [provided by RefSeq, Jul 2008]

uniprot summary :

CFI: Responsible for cleaving the alpha-chains of C4b and C3b in the presence of the cofactors C4-binding protein and factor H respectively. Defects in CFI are a cause of susceptibility to hemolytic uremic syndrome atypical type 3 (AHUS3). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Defects in CFI are the cause of complement factor I deficiency (CFI deficiency). CFI deficiency is an autosomal recessive condition associated with a propensity to pyogenic infections. Belongs to the peptidase S1 family. Protein type: Protease; EC 3.4.21.45; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 4q25. Cellular Component: extracellular space; membrane; extracellular region; nucleus. Molecular Function: metal ion binding; serine-type endopeptidase activity; scavenger receptor activity. Biological Process: receptor-mediated endocytosis; regulation of complement activation; innate immune response; proteolysis; complement activation, classical pathway. Disease: Macular Degeneration, Age-related, 13; Complement Factor I Deficiency; Hemolytic Uremic Syndrome, Atypical, Susceptibility To, 3

size1 :

0.01 mg

price1 :

185 USD

size2 :

0.05 mg

price2 :

385

size3 :

0.1 mg

price3 :

595

more info or order :

MyBioSource product webpage